Abstract: A continuous process for producing microspheres wherein small particle sizes can be obtained without the problem of foaming. A drug and polymer containing dispersed phase is continuously introduced into a high intensity emulsification vessel along with a continuous phase. An emulsion of the dispersed phase is formed in the continuous phase by high intensity mixing effective to quickly solidify the dispersed phase polymer without having to take steps to address foaming.

Abstract: Solid drug forms obtainable by extrusion of a melt comprising, besides one or more active substances, a mixture of homo- and/or copolymers of N-vinylpyrrolidone and degraded starches.

Abstract: A powdery pharmaceutical composition comprising nicotine or a derivative thereof and starch microspheres. The starch microspheres are preferably degradable epichlorhydrin cross-linked starch microspheres. The average diameter of the microspheres is from around 1 .mu.m to around 200 .mu.m, preferably around 45 .mu.m. The invention also encompasses a method for manufacturing a powdery pharmaceutical composition comprising nicotine and starch microspheres. The invention further comprises a method of diminishing the desire of a subject to use tobacco which comprises the step of administering to the subject the above powdery pharmaceutical composition.

Abstract: The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epichelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients.

Abstract: A percutaneously administrable base composition which facilitates the percutaneous absorption of drugs and is remarkably reduced in the irritancy against the skin. The composition comprises 10-60 wt. % of lower alcohol, 10-50 wt. % of humectant, 10-70 wt. % of water, 0.1-15 wt. % of abirritant and 0.1-15 wt. % of absorption promoter. A drug composition is prepared by adding to the above composition various active ingredients such as antitussive, expectorant, skeletal muscle relaxant, antivertiginous drug, narcotic, drug for the circulatory system, and so forth.

Abstract: Disclosed are budesonide pellets with a controlled release pattern containing, from the inside to the outside: a) neutral pellets; b) an active principle layer of micronized budesonide and one or more water-soluble auxiliaries; c) a first lacquer coating consisting of 80 to 97% of at least one lacquer insoluble in gastric fluids but soluble in intestinal fluids and 3 to 20% of at least one lacquer insoluble in both gastric and intestinal fluids; and d) a second lacquer coating consisting of at least one lacquer insoluble in gastric and intestinal fluids. The invention also relates to a process for producing budesonide pellets with a controlled release pattern.

Abstract: A method for enhancing a stable concentration of cellular creatine in a human includes dissolving an effervescent containing an acidic edible salt form of creatine in water. Once the mixture has completely dissolved the solution is immediately ingested, and an effective amount of creatine is absorbed. Preferably, the effervescent is in the form of a tablet which contains creatine in the form of an edible salt, a mixture of acids, and sodium.

Abstract: The present invention relates to expanded solid compositions whose matrix comprises a cellular network formed from a starch-rich product and contains at least some expanded thermoplastic hollow particles of polymer or copolymer of an ethylenically unsaturated monomer or mixture of such monomers. These compositions constitute new dosage forms for cosmetic or dermatological use. These compositions either take the form of expanded cylinders, pellets, leaves or flakes, or the form of powder. When reduced to the powder state, they may also be used as a make-up or hygiene composition to be rehydrated or to be used as such.

Abstract: A controlled release dosage form which comprises:(a) a homogeneous compressed core which comprises a compressed granulation of:(i) particles of a calcium channel blocker compound coated with an enteric polymer that are dispersed onto a solid pharmaceutical filler; and(b) a continuous compressed outer layer around said homogeneous compressed core which comprises a compressed granulation of:(i) one or more pharmaceutically acceptable polymers which form a hydrogel in which calcium channel blocker compound is dispersed.

Abstract: The present invention relates to a sustained release formulation used for treatment or prevention of the diseases, which contains a therapeutically effective substance as an active ingredient, collagen as a drug carrier, and glycosaminoglycan as an additive. The formulation allows controlled release of the therapeutically effective substance.

Abstract: The invention provides an agglomerate composition composed of units of aggregated fine particles and methods for its manufacture and use. The agglomerate composition units are composed of fine particles having a mean particle size in the range of 1 .mu.m to 5 .mu.m, and usually includes a medicament powder. The agglomerate units have a mean size in the range from 200 .mu.m to 500 .mu.m and have a friability index in the range from about 10 to 60.

Abstract: Submicron size particles of pharmaceutical or other water-insoluble or poorly water-insoluble substances are prepared using a combination of one or more surface modifiers/surfactants such as polaxomers, poloxamines, polyoxyethylene sorbitan fatty acid esters and the like together with natural or synthetic phospholipids. Particles so produced have a volume weighted mean particle size at least one-half smaller than obtainable using a phospholipid alone. Compositions so prepared are resistant to particle size growth on storage.

Abstract: A substantially flexible, dry matrix with antimicrobial properties is made from a matrix comprising natural or synthetic, woven, non-woven or knitted fibers, said matrix having been uniformly coated with an amount of a non-aqueous treatment solution sufficient to allow said matrix to retain its substantially dry characteristics. In a preferred embodiment, said non-aqueous treatment solution has between about 70% and 99% of at least one glycol compound, between about 1% and 15% of a PVP-iodine and optionally between about 0 and 15% of a non-ionic surfactant.Also, skin is treated to prevent disease, such as the disinfecting of teats on dairy cows during milking, by wiping the skin with the article.

Abstract: The invention provides a pharmaceutically acceptable solid oral formulation of olanzapine and a process for making such formulation.

Abstract: A liquid oil and fat ingredient or others are carried by pores of a porous carrier composed of porous starch grain obtained by reacting an enzyme having raw starch digestive activity onto the starch. With starch being used as porous carrier, the powder preparation according to the present invention is not harmful to the human body, it can be supplied continuously in great volumes, manufactured cheaply without difficult processing, and moreover, being completely biodegradable, this powder preparation does not cause any environmental problems. It can be used in various industrial fields.

Abstract: The present invention relates to nanoparticles, and in particular nanocapsules, provided with a lamellar coating obtained from a silicone surfactant, and to their use in a composition, in particular a topical composition, for treatment of the skin, mucosae, nails, scalp and/or hair.

Abstract: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts as a stabilizing agent). In particular, protein and pharmacologically active agent in a biocompatible dispersing medium are subjected to high shear, in the absence of any conventional surfactants, and also in the absence of any polymeric core material for the particles. The procedure yields particles with a diameter of less than about 1 micron. The use of specific composition and preparation conditions (e.g., addition of a polar solvent to the organic phase), and careful selection of the proper organic phase and phase fraction, enables the reproducible production of unusually small nanoparticles of less than 200 nm diameter, which can be sterile-filtered.

Abstract: The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small intestine and a colon with a lumen therethrough having an inlet to the colon from the small intestine, comprising:a. a safe and effective amount of a therapeutically active agent incorporated into a compressed, bi-convex tablet, with a maximum diameter of about 4 mm to about 10 mm;b. a non-pH dependent smoothing coat applied to the tablet to provide a smooth tablet surface free from edges or sharp curves; andc. an enteric polymer coating material comprising at least one inner coating layer and only one outer coating layer;wherein the therapeutically active agent is released at a point near the inlet to, or within the colon; each of the inner coating layer(s) is an enteric polymer that begins to dissolve in an aqueous media at a pH between about 5 to about 6.

Abstract: An improved animal lure and cover scent process and product employs a combustible absorbent material impregnated with an aromatic substance having fragrance attractive to an animal, with the absorbent material being of restricted combustibility such that the absorbent material tends to smoke without producing a flame as it burns, the smoke entraining the fragrance with it as it travels through the air. The combustible absorbent material of the present invention is in the form of an incense stick wherein a cellulosic material formed from sawdust is coated on one end of a combustible bamboo stick. A weather shield protects the incense stick from wind and rain.

Abstract: A washing agent which comprises spherical particles having an average particle diameter in the range of about 2 to 40 microns, at least a surface portion of which particles comprises or consists of, or consists essentially or substantially of a calcium phosphate compound having a Ca/P ratio in the range of about 1.0 to 2.0, and spherical particles having an average particle diameter in the range of about 80 to 200 microns, at least a surface portion of which particles comprises or consists of, or consists essentially or substantially of a calcium phosphate compound having a Ca/P ratio in the range of about 1.0 to 2.0. The washing agent, when used in cleaning of the feet and elbows, can remove a wide variety of bacteria, thereby making the feet and elbows clean, in addition to removing the aged and deteriorated cuticles.